protein tyrosine phosphatase receptor type SGenealiases: PTP-sigma · PTPSIGMA · R-PTP-S · R-PTP-sigma
Q-omics provides the consensus-scored PTPRS profile across patient tissues and cancer cell-line models. PTPRS expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTPRS is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, PTPRS protein abundance shows 32,144 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KICH, and GBM as cancer lineages where PTPRS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPRS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPRS survival associations across molecular data types. PTPRS RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPRS RNA expression–survival associations across cancer types. High PTPRS expression shows unfavorable associations in ACC, KIRP and SKCM, but favorable associations in HNSC, PAAD and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for PTPRS RNA expression.
This table summarizes PTPRS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PTPRS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPRS shows lower tumor expression in KICH, LUAD, BRCA and COAD and higher tumor expression in LUSC and KIRP. The KICH box plot shows higher PTPRS RNA expression in normal versus tumor tissue (log2 FC = −3.021, t-test p < 0.001).
This table shows molecular features associated with PTPRS in patient tissues and cancer cell lines. In patient samples, PTPRS shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPRS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
